VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumab

Journal of Neuro-Oncology

Volumn 121, Issue 3, 2015, Pages 499-504

  Di Stefano, Anna Luisa ^a,b,c   Labussiere, Marianne ^a   Lombardi, Giuseppe ^d   Eoli, Marica ^e   Bianchessi, Donata ^e   Pasqualetti, Francesco ^f   Farina, Patrizia ^b,d   Cuzzubbo, Stefania ^b,e   Gallego Perez Larraya, Jaime ^a,b,g   Boisselier, Blandine ^a   Ducray, Francois ^a   Cheneau, Caroline ^a   Moglia, Arrigo ^c   Finocchiaro, Gaetano ^e   Marie, Yannick ^h   Rahimian, Amithys ^a,i   Hoang Xuan, Khe ^a,b   Delattre, Jean Yves ^a,b,i   Mokhtari, Karima ^a,b,i   Sanson, Marc ^a,b,i  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIVERSITY OF PAVIA   (Italy)

^d VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^e DEPARTMENT OF NEUROSURGERY   (Italy)

^f UNIVERSITY HOSPITAL OF PISA   (Italy)

^g UNIVERSITY CLINIC OF NAVARRA   (Spain)

^h INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

ⁱ Onconeurothèque   (France)

Author keywords

Bevacizumab; Glioblastoma; rs2010963; SNP; VEGF

Indexed keywords

BEVACIZUMAB; FOTEMUSTINE; IRINOTECAN; TEMOZOLOMIDE; VASCULOTROPIN A; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VEGFA PROTEIN, HUMAN;

5' UNTRANSLATED REGION; ALLELE; ARTICLE; BLEEDING; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; DISEASE ASSOCIATION; DRUG RESPONSE; DRUG WITHDRAWAL; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; GLIOBLASTOMA; HEMATOMA; HUMAN; INTRATUMORAL HEMATOMA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHLEBITIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOSIS; TOXICITY; TUMOR BLEEDING; TUMOR RECURRENCE; VASCULAR TOXICITY; VEGFA GENE; VEIN THROMBOSIS; BLOOD; BRAIN NEOPLASMS; CHEMICALLY INDUCED; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; HEMORRHAGE; KAPLAN MEIER METHOD; MORTALITY; NEOPLASM RECURRENCE, LOCAL;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENOTYPE; GLIOBLASTOMA; HEMORRHAGE; HUMANS; KAPLAN-MEIER ESTIMATE; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, SINGLE NUCLEOTIDE; THROMBOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84925539745     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-014-1677-x     Document Type: Article

References (27)

1. Kunnakkat S, Narayana A (2011) Bevacizumab in the treatment of high-grade gliomas: an overview. Angiogenesis 14:423–430
2. Jensen RL (1998) Growth factor-mediated angiogenesis in the malignant progression of glial tumors: a review. Surg Neurol 49:189–195; discussion 196
3. Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733–4740
4. Kreisl TN, Kim L, Moore K et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740–745
5. Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722–4729
6. Gil MJ, de Penas Las R, Reynes G et al (2012) Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish neuro-oncology research group (GEINO). Anticancer Drugs 23:659–665
7. GKB P. http://www.pharmgkb.org/ [online]. Available at: http://www.pharmgkb.org/
8. Brogan IJ, Khan N, Isaac K, Hutchinson JA, Pravica V, Hutchinson IV (1999) Novel polymorphisms in the promoter and 5′ UTR regions of the human vascular endothelial growth factor gene. Hum Immunol 60:1245–1249
9. Tischer E, Mitchell R, Hartman T et al (1991) The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266:11947–11954
10. Minchenko A, Salceda S, Bauer T, Caro J (1994) Hypoxia regulatory elements of the human vascular endothelial growth factor gene. Cell Mol Biol Res 40:35–39
11. Schultz A, Lavie L, Hochberg I et al (1999) Interindividual heterogeneity in the hypoxic regulation of VEGF: significance for the development of the coronary artery collateral circulation. Circulation 100:547–552
12. Jain L, Vargo CA, Danesi R et al (2009) The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther 8:2496–2508
13. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE (2000) Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12:1232–1235
14. Zhai R, Liu G, Zhou W et al (2008) Vascular endothelial growth factor genotypes, haplotypes, gender, and the risk of non-small cell lung cancer. Clin Cancer Res 14:612–617
15. Sfar S, Hassen E, Saad H, Mosbah F, Chouchane L (2006) Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome. Cytokine 35:21–28
16. Li R, Zhao Y, Fan W et al (2011) Possible association between polymorphisms of human vascular endothelial growth factor a gene and susceptibility to glioma in a Chinese population. Int J Cancer 128:166–175
17. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996
18. Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972
19. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) WHO Classification of tumours of the central nervous system. Acta Neuropathol 114:97–109
20. Petrovic D, Verhovec R, Globocnik Petrovic M, Osredkar J, Peterlin B (2007) Association of vascular endothelial growth factor gene polymorphism with myocardial infarction in patients with type 2 diabetes. Cardiology 107:291–295
21. Awata T, Inoue K, Kurihara S et al (2002) A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 51:1635–1639
22. Inoue M, Itoh H, Ueda M et al (1998) Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 98:2108–2116
23. Petrovic MG, Korosec P, Kosnik M et al (2008) Local and genetic determinants of vascular endothelial growth factor expression in advanced proliferative diabetic retinopathy. Mol Vis 14:1382–1387
24. van der Meer P, De Boer RA, White HL et al (2005) The VEGF +405 CC promoter polymorphism is associated with an impaired prognosis in patients with chronic heart failure: a MERIT-HF substudy. J Card Fail 11:279–284
25. Vailati FB, Crispim D, Sortica DA, Souza BM, Brondani LA, Canani LH (2012) The C allele of -634G/C polymorphism in the VEGFA gene is associated with increased VEGFA gene expression in human retinal tissue. Invest Ophthalmol Vis Sci 53:6411–6415
26. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S (2008) Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300:2277–2285
27. Hapani S, Sher A, Chu D, Wu S (2010) Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology 79:27–38